Home/Filings/4/0001012975-25-000791
4//SEC Filing

CRANDELL KEITH 4

Accession 0001012975-25-000791

CIK 0002040807other

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 6:34 PM ET

Size

23.3 KB

Accession

0001012975-25-000791

Insider Transaction Report

Form 4
Period: 2025-11-13
NELSEN ROBERT
Director10% Owner
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
CRANDELL KEITH
Director10% Owner
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
GILLIS STEVEN
Director10% Owner
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
Transactions
  • Disposition to Issuer

    Common Stock

    2025-11-1318,503,1280 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2025-11-138,313,6800 total(indirect: See Footnote)
Footnotes (4)
  • [F1]Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus
  • [F2](Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
  • [F3]Represents shares held directly by ARCH Venture Fund XII, L.P ("ARCH Venture Fund XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. ARCH Venture Partners XII, LLC ("AVP XII LLC"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares. Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.
  • [F4]Represents shares held directly by ARCH Venture Fund XIII, L.P. ("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

Issuer

Metsera, Inc.

CIK 0002040807

Entity typeother

Related Parties

1
  • filerCIK 0001219039

Filing Metadata

Form type
4
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 6:34 PM ET
Size
23.3 KB